Evaluation of Repeat Administration of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC-E): An Open-Label Safety Extension Trial Assessing Repeat Administration of MST-188 (Purified Poloxamer 188) Injection in Subjects With Sickle Cell Disease Experiencing Vaso Occlusive Crisis

Trial Profile

Evaluation of Repeat Administration of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC-E): An Open-Label Safety Extension Trial Assessing Repeat Administration of MST-188 (Purified Poloxamer 188) Injection in Subjects With Sickle Cell Disease Experiencing Vaso Occlusive Crisis

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2016

At a glance

  • Drugs Poloxamer 188 (Primary)
  • Indications Sickle cell anaemia; Veno-occlusive disorders
  • Focus Adverse reactions
  • Acronyms EPIC-E
  • Sponsors Amgen; Mast Therapeutics
  • Most Recent Events

    • 26 Oct 2016 Status changed from recruiting to completed.
    • 13 Jul 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 26 May 2015 According to a Mast Therapeutics media release, this study is expected to remain open for approximately one year.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top